Literature DB >> 352213

Vancomycin revisited.

F V Cook, W E Farrar.   

Abstract

Vancomycin, virtually discarded after development of antistaphylococcal penicillins, has recently been receiving renewed attention. There are several clinical situations in which it appears to offer advantages over other available antimicrobial agents: infections due to methicillin-resistant staphylococci; bacterial endocarditis in patients allergic to penicillin; staphylococcal enterocolitis; staphylococcal infection in patients undergoing hemodialysis; infections caused by penicillin-resistant diphtheroids; and prophylaxis of bacterial endocarditis in patients with prosthetic valves or penicillin allergy. Its penetration into the cerebrospinal fluid suggests that vancomycin may be useful in treating certain infections of the central nervous system. Although its ototoxic and nephrotoxic potential cannot be ignored, these problems can be minimized by keeping the serum concentration at the proper level.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 352213     DOI: 10.7326/0003-4819-88-6-813

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  47 in total

1.  Effects of arbekacin and vancomycin on release of lactate dehydrogenase and fragmentation of DNA in LLC-PK1 kidney epithelial cells.

Authors:  T Nakamura; T Kokuryo; M Okuda; Y Hashimoto; K Inui
Journal:  Pharm Res       Date:  1999-07       Impact factor: 4.200

Review 2.  Vancomycin- and erythromycin-induced hearing loss in humans.

Authors:  R E Brummett; K E Fox
Journal:  Antimicrob Agents Chemother       Date:  1989-06       Impact factor: 5.191

3.  Mycobacterium avium-M. intracellulare and Acquired Immunodeficiency Syndrome.

Authors:  E Wolinsky; C R Horsburgh; D L Cohn; R B Roberts; H Masur; R Miller; A Y Tsang; M D Iseman
Journal:  Antimicrob Agents Chemother       Date:  1987-06       Impact factor: 5.191

4.  Enhanced clearance of vancomycin by hemodialysis in a child.

Authors:  R Schoumacher; R L Chevalier; R A Gomez; A D Rogol; R Cummings; D A Spyker
Journal:  Pediatr Nephrol       Date:  1989-01       Impact factor: 3.714

5.  Gentamicin-resistant enterococci and endocarditis.

Authors:  R Holliman; E Smyth
Journal:  Postgrad Med J       Date:  1989-06       Impact factor: 2.401

6.  Sensitive radioimmunoassay for vancomycin.

Authors:  K L Fong; D H Ho; L Bogerd; T Pan; N S Brown; L Gentry; G P Bodey
Journal:  Antimicrob Agents Chemother       Date:  1981-01       Impact factor: 5.191

Review 7.  Clinical pharmacokinetics of vancomycin.

Authors:  G R Matzke; G G Zhanel; D R Guay
Journal:  Clin Pharmacokinet       Date:  1986 Jul-Aug       Impact factor: 6.447

8.  Randomized comparison between two ceftazidime-containing regimens and cephalothin-gentamicin-carbenicillin in febrile granulocytopenic cancer patients.

Authors:  B S Kramer; R Ramphal; K H Rand
Journal:  Antimicrob Agents Chemother       Date:  1986-07       Impact factor: 5.191

9.  Interactions between antibiotics and human neutrophils in the killing of staphylococci.

Authors:  R K Root; R Isturiz; A Molavi; J A Metcalf; H L Malech
Journal:  J Clin Invest       Date:  1981-01       Impact factor: 14.808

10.  Effects of hepatic function on vancomycin clinical pharmacology.

Authors:  N Brown; D H Ho; K L Fong; L Bogerd; A Maksymiuk; R Bolivar; V Fainstein; G P Bodey
Journal:  Antimicrob Agents Chemother       Date:  1983-04       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.